Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Liver Histology01:27

Liver Histology

4.9K
The microscopic anatomy of the liver is a complex and intricate system that comprises numerous structural units known as liver lobules, each of which is comparable in size to a sesame seed. These hexagonal structures consist of plates of liver cells or hepatocytes, which are characterized by their versatility and abundance of cellular apparatus like rough and smooth ER, Golgi apparatus, peroxisomes, and mitochondria.
Hepatocytes perform a variety of essential functions. They secrete...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathological characteristics of sonic hedgehog hepatocellular adenomas with special focus on small lesions.

Histopathology·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology international·2026
Same author

Increasing Case Numbers and Earlier Age at Diagnosis of Alveolar Echinococcosis: Insights from a 13-Year Retrospective Swiss Study.

Pathogens (Basel, Switzerland)·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology (Baltimore, Md.)·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Annals of hepatology·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Journal of hepatology·2026

Related Experiment Video

Updated: Mar 2, 2026

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
08:15

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

Published on: February 2, 2024

1.6K

Hepatocellular Adenomas: Morphology and Genomics.

Paulette Bioulac-Sage1, Christine Sempoux2, Charles Balabaud1

  • 1Inserm U 1053, Université Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France.

Gastroenterology Clinics of North America
|May 17, 2017
PubMed
Summary

Hepatocellular adenomas (HCAs) are rare tumors classified into three subtypes based on genetic mutations. Immunohistochemical markers help identify these subtypes and assess malignant transformation risk, particularly for beta-catenin activated HCAs.

Keywords:
GenomicsGenoptye/phenotypeHepatocellular adenoma classificationHepatocellular adenomasMalignant transformation

More Related Videos

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.7K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

37.3K

Related Experiment Videos

Last Updated: Mar 2, 2026

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
08:15

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

Published on: February 2, 2024

1.6K
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.7K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

37.3K

Area of Science:

  • Hepatology
  • Oncology
  • Molecular Pathology

Background:

  • Hepatocellular adenomas (HCAs) are rare benign liver tumors.
  • Previously considered a single entity, HCAs are now classified into three distinct subtypes based on specific molecular drivers.
  • Understanding these subtypes is crucial for assessing malignant transformation risk.

Purpose of the Study:

  • To detail the classification of Hepatocellular adenomas (HCAs) into three main subtypes.
  • To highlight the specific mutations associated with each HCA subtype: HNF1α-inactivated, inflammatory (STAT3 pathway activation), and β-catenin-activated (CTNNB1 mutations).
  • To emphasize the role of immunohistochemical markers in identifying HCA subtypes and evaluating the risk of malignant transformation, particularly related to β-catenin activation levels.

Main Methods:

  • Utilizing specific immunohistochemical markers.
  • Analyzing mutations in HNF1α and CTNNB1 genes.
  • Assessing STAT3 pathway activation.
  • Correlating molecular findings with HCA subtypes and malignant potential.

Main Results:

  • Hepatocellular adenomas (HCAs) are categorized into HNF1α-inactivated, inflammatory, and β-catenin-activated subtypes.
  • Inflammatory HCAs are linked to mutations activating the STAT3 pathway.
  • β-catenin-activated HCAs, particularly those with exon 3 mutations (including S45), show a higher risk of malignant transformation.
  • Immunohistochemistry effectively identifies these subtypes and the degree of β-catenin activation.
  • Fewer than 10% of HCAs remain unclassified.

Conclusions:

  • Hepatocellular adenomas (HCAs) can be reliably classified into three main subtypes using molecular and immunohistochemical approaches.
  • The identification of specific mutations and pathways (HNF1α, STAT3, β-catenin) is key to subtyping HCAs.
  • Assessing β-catenin activation levels is critical for predicting the risk of malignant transformation in HCAs.